Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia

Ya Bin Ma, Paul Chan, Yuzhen Zhang, Brian Tomlinson, Zhongmin Liu

研究成果: 雜誌貢獻文章

摘要

Introduction: Cardiovascular disease is a major cause of morbidity and mortality throughout the world and hypercholesterolemia is one of the key risk factors. Statins are the first line treatment to reduce atherogenic lipids and there is substantial and robust evidence with atorvastatin for reduction of cardiovascular events and mortality. Ezetimibe can be combined with any dose of atorvastatin for incremental lipid-lowering effects. Areas covered: In this review, the authors summarize the pharmacokinetics, pharmacodynamics and clinical efficacy of the components and the combination of ezetimibe and atorvastatin. Clinical benefits have been seen with ezetimibe combined with simvastatin but studies of its combination with atorvastatin are generally limited to the effects on lipid parameters where the addition of ezetimibe to atorvastatin is generally more effective than titrating the atorvastatin dose. Expert opinion: Although there are no cardiovascular outcomes studies with the combination of ezetimibe and atorvastatin, the greater reduction in atherogenic lipids can be assumed to have greater benefits in reducing cardiovascular events. The ezetimibe–atorvastatin combination is very effective in this respect and well tolerated. Fixed-dose combinations improve medication adherence and this combination should be useful for patients who cannot reach their lipid targets with maximally tolerated statin doses.
原文英語
頁(從 - 到)917-928
頁數12
期刊Expert Opinion on Pharmacotherapy
20
發行號8
DOIs
出版狀態已發佈 - 五月 24 2019

指紋

Hypercholesterolemia
Safety
Lipids
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Therapeutics
Simvastatin
Medication Adherence
Maximum Tolerated Dose
Mortality
Expert Testimony
Atorvastatin Calcium
Ezetimibe
Cardiovascular Diseases
Pharmacokinetics
Outcome Assessment (Health Care)
Morbidity

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

引用此文

Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia. / Ma, Ya Bin; Chan, Paul; Zhang, Yuzhen; Tomlinson, Brian; Liu, Zhongmin.

於: Expert Opinion on Pharmacotherapy, 卷 20, 編號 8, 24.05.2019, p. 917-928.

研究成果: 雜誌貢獻文章

@article{d35e7db680a247a294a993b498f5eeb6,
title = "Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia",
abstract = "Introduction: Cardiovascular disease is a major cause of morbidity and mortality throughout the world and hypercholesterolemia is one of the key risk factors. Statins are the first line treatment to reduce atherogenic lipids and there is substantial and robust evidence with atorvastatin for reduction of cardiovascular events and mortality. Ezetimibe can be combined with any dose of atorvastatin for incremental lipid-lowering effects. Areas covered: In this review, the authors summarize the pharmacokinetics, pharmacodynamics and clinical efficacy of the components and the combination of ezetimibe and atorvastatin. Clinical benefits have been seen with ezetimibe combined with simvastatin but studies of its combination with atorvastatin are generally limited to the effects on lipid parameters where the addition of ezetimibe to atorvastatin is generally more effective than titrating the atorvastatin dose. Expert opinion: Although there are no cardiovascular outcomes studies with the combination of ezetimibe and atorvastatin, the greater reduction in atherogenic lipids can be assumed to have greater benefits in reducing cardiovascular events. The ezetimibe–atorvastatin combination is very effective in this respect and well tolerated. Fixed-dose combinations improve medication adherence and this combination should be useful for patients who cannot reach their lipid targets with maximally tolerated statin doses.",
keywords = "Atorvastatin, ezetimibe, fixed dose combination, hypercholesterolemia",
author = "Ma, {Ya Bin} and Paul Chan and Yuzhen Zhang and Brian Tomlinson and Zhongmin Liu",
year = "2019",
month = "5",
day = "24",
doi = "10.1080/14656566.2019.1594776",
language = "English",
volume = "20",
pages = "917--928",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia

AU - Ma, Ya Bin

AU - Chan, Paul

AU - Zhang, Yuzhen

AU - Tomlinson, Brian

AU - Liu, Zhongmin

PY - 2019/5/24

Y1 - 2019/5/24

N2 - Introduction: Cardiovascular disease is a major cause of morbidity and mortality throughout the world and hypercholesterolemia is one of the key risk factors. Statins are the first line treatment to reduce atherogenic lipids and there is substantial and robust evidence with atorvastatin for reduction of cardiovascular events and mortality. Ezetimibe can be combined with any dose of atorvastatin for incremental lipid-lowering effects. Areas covered: In this review, the authors summarize the pharmacokinetics, pharmacodynamics and clinical efficacy of the components and the combination of ezetimibe and atorvastatin. Clinical benefits have been seen with ezetimibe combined with simvastatin but studies of its combination with atorvastatin are generally limited to the effects on lipid parameters where the addition of ezetimibe to atorvastatin is generally more effective than titrating the atorvastatin dose. Expert opinion: Although there are no cardiovascular outcomes studies with the combination of ezetimibe and atorvastatin, the greater reduction in atherogenic lipids can be assumed to have greater benefits in reducing cardiovascular events. The ezetimibe–atorvastatin combination is very effective in this respect and well tolerated. Fixed-dose combinations improve medication adherence and this combination should be useful for patients who cannot reach their lipid targets with maximally tolerated statin doses.

AB - Introduction: Cardiovascular disease is a major cause of morbidity and mortality throughout the world and hypercholesterolemia is one of the key risk factors. Statins are the first line treatment to reduce atherogenic lipids and there is substantial and robust evidence with atorvastatin for reduction of cardiovascular events and mortality. Ezetimibe can be combined with any dose of atorvastatin for incremental lipid-lowering effects. Areas covered: In this review, the authors summarize the pharmacokinetics, pharmacodynamics and clinical efficacy of the components and the combination of ezetimibe and atorvastatin. Clinical benefits have been seen with ezetimibe combined with simvastatin but studies of its combination with atorvastatin are generally limited to the effects on lipid parameters where the addition of ezetimibe to atorvastatin is generally more effective than titrating the atorvastatin dose. Expert opinion: Although there are no cardiovascular outcomes studies with the combination of ezetimibe and atorvastatin, the greater reduction in atherogenic lipids can be assumed to have greater benefits in reducing cardiovascular events. The ezetimibe–atorvastatin combination is very effective in this respect and well tolerated. Fixed-dose combinations improve medication adherence and this combination should be useful for patients who cannot reach their lipid targets with maximally tolerated statin doses.

KW - Atorvastatin

KW - ezetimibe

KW - fixed dose combination

KW - hypercholesterolemia

UR - http://www.scopus.com/inward/record.url?scp=85063583529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063583529&partnerID=8YFLogxK

U2 - 10.1080/14656566.2019.1594776

DO - 10.1080/14656566.2019.1594776

M3 - Article

C2 - 30908086

AN - SCOPUS:85063583529

VL - 20

SP - 917

EP - 928

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 8

ER -